National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

aflibercept
A protein comprised of segments of the extracellular domains of human vascular endothelial growth factor receptors 1 (VEGFR1) and 2 (VEGFR2) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their cell receptors. Disruption of the binding of VEGFs to their cell receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:vascular endothelial growth factor trap
VEGF Trap
VEGF Trap R1R2



Previous:aerosol sargramostim, aerosolized liposomal 9-nitro-20 (S) camptothecin, Affinitac, Affinitak, Afinitor
Next:Aflodac, AFP gene hepatocellular carcinoma vaccine, AFP464, AG-024322, agatolimod sodium

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov